Next generation of immune checkpoint inhibitors and beyond
Julian A. Marin‐Acevedo(Indiana University Health), Yanyan Lou(WinnMed)
Cited by 537
Related Papers
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
|Journal of Hematology & Oncology|2021|271
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
|Journal for ImmunoTherapy of Cancer|2022|140
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study
|The Lancet Digital Health|2023|108